Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia

Fludarabine, cyclophosphamide, and rituximab (FCR) has represented a significant treatment advancement in chronic lymphocytic leukemia (CLL). In the new scenario of targeted agents, there is an increasing interest in identifying patients who gain the maximum benefit from FCR. In this observational m...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Blood
Κύριοι συγγραφείς: Rossi, Davide, Terzi-di-Bergamo, Lodovico, De Paoli, Lorenzo, Cerri, Michaela, Ghilardi, Guido, Chiarenza, Annalisa, Bulian, Pietro, Visco, Carlo, Mauro, Francesca R., Morabito, Fortunato, Cortelezzi, Agostino, Zaja, Francesco, Forconi, Francesco, Laurenti, Luca, Del Giudice, Ilaria, Gentile, Massimo, Vincelli, Iolanda, Motta, Marina, Coscia, Marta, Rigolin, Gian Matteo, Tedeschi, Alessandra, Neri, Antonino, Marasca, Roberto, Perbellini, Omar, Moreno, Carol, Del Poeta, Giovanni, Massaia, Massimo, Zinzani, Pier Luigi, Montillo, Marco, Cuneo, Antonio, Gattei, Valter, Foà, Robin, Gaidano, Gianluca
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Hematology 2015
Θέματα:
Lymphoid Neoplasia
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4743433/
https://ncbi.nlm.nih.gov/pubmed/26276669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-05-647925
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια